Gaining 'Insight' on Cardiac Insight’s Recent Surge

Let’s Talk Medtech spoke with Dave Hadley, Phd, Senior VP of Research & Development of Cardiac Insight, about the company and the exploding ECG market.

Omar Ford

May 26, 2021

1 Min Read
IMG_May262021at14708PM.jpg
spaxiax - stock.adobe.com

Cardiac Insight is seeing a major uptick in ECG screenings. The Seattle, WA-based company reported there was more than a 70% surge in sales of the Cardea 20/20 ECG in 1Q21.

Let’s Talk Medtech recently spoke with Dave Hadley, Phd, Senior VP of Research & Development. He is the inventor of Cardea 20/20, about the surge and recent interest in the ECG market. Dr. Hadley has more than 30 years of hands-on experience blending customer needs with information technology through research and development. 

Cardiac Insight was named a finalist for this year’s Medical Design Excellence Awards.

Click here to access the most recent episode of Let's Talk Medtech. 

 

 

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like